Transparency Notification Received from ABO Infinium Americas OpCo LTD
REGULATED INFORMATION
Article 14 of the Law of 2 May 2007 on Disclosure of Major Holdings
Mont-Saint-Guibert, Belgium - BioSenic S.A. (Euronext Brussels and Paris: BIOS), a clinical-stage company dedicated to addressing severe autoimmune and inflammatory diseases as well as cell therapy, has announced that it has received a transparency notification from ABO Infinium Americas OpCo LTD. Below are the details of this notification, and the complete text is available on the BioSenic website under "Major shareholders & transparency notices."
This notification reveals that the voting rights associated with BioSenic's shares held by ABO Infinium Americas OpCo LTD have dropped below the 5% threshold due to a transfer of shares.
The notification from ABO Infinium Americas OpCo LTD, dated August 16, 2024, includes the following details:
- Reason for Notification: Acquisition or transfer of voting securities or voting rights
- Notification By: A parent company or controlling person
- Person Subject to the Notification Requirement:
- ABO Infinium Americas OpCo LTD
- ABO Securities
- Omega Financial Corporation
- Mr. Pierre Vannineuse
- Transaction Date: August 14, 2024
- Threshold Crossed: 5%
- Denominator: 251,312,817
- Full Chain of Controlled Undertakings: ABO Infinium Americas OpCo LTD (303 Shriley Street, Nassau, Bahamas) is fully owned by ABO Securities (71 Fort Street, Georges Town, Grand Cayman, Cayman Islands). ABO Securities is completely controlled by Omega Financial Corporation (71 Fort Street, Georges Town, Grand Cayman, Cayman Islands), which is entirely owned by Pierre Vannineuse.
About BioSenic
BioSenic is a leading biotech company focused on developing clinical assets from its Medsenic’s arsenic trioxide (ATO) platform. The main target indications within its autoimmune platform include graft-versus-host disease (GvHD), systemic lupus erythematosus (SLE), and now systemic sclerosis (SSc).
After a merger in October 2022, BioSenic combined the strategic strengths of Medsenic and Bone Therapeutics. This merger enables Medsenic/BioSenic to investigate a new array of anti-inflammatory and anti-autoimmune formulations that leverage the immunomodulatory properties of ATO and oral ATO (OATO).
BioSenic is situated in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. More information about BioSenic can be found at http://www.biosenic.com.
About the Main Medsenic/BioSenic Technology Platform
The ATO platform generates active products with immunomodulatory effects on activated immune cells. One significant application is its use in onco-immunology for treating chronic graft-versus-host disease (cGvHD), which poses considerable challenges for long-term survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Medsenic has successfully completed a phase 2 trial with its intravenous formulation, Arscimed, which has received orphan drug designation from both the FDA and EMA. The company is now preparing for an international phase 3 confirmatory study with its new OATO formulation. Additionally, the platform aims to address moderate-to-severe systemic lupus erythematosus (SLE) using the same OATO formulation, which has shown safety and efficacy across various affected organs. Systemic sclerosis has also been integrated into the clinical pipeline of Medsenic/BioSenic. This serious chronic condition affects the skin, lungs, and vascularization and currently lacks effective treatments. Positive preclinical studies on relevant animal models support the development of a phase 2 clinical protocol utilizing innovative immunomodulatory formulations of recognized APIs that activate the immune system.
The company is concentrating its R&D and clinical efforts on the rapid growth of its autoimmune platform.
Moreover, BioSenic is renewing its focus on its allogeneic cell therapy platform, which originated from Bone Therapeutics. This involves using differentiated bone marrow Mesenchymal Stromal Cells (MSCs) to isolate and refine biological subcellular components. These cells may result in new vesicles that offer a unique approach to organ repair. BioSenic is currently working on identifying new patentable methodologies in this complex therapeutic area.
For Further Information, Please Contact:
BioSenic SA
François Rieger, PhD, CEO
Tel: +33 (0)671 73 31 59
investorrelations@biosenic.com
Frequently Asked Questions
1. What is the significance of the transparency notification received by BioSenic?
The transparency notification indicates that the voting rights associated with BioSenic's shares held by ABO Infinium Americas OpCo LTD have decreased below the 5% threshold due to share transfers.
2. What can you tell me about BioSenic's focus areas?
BioSenic specializes in developing clinical assets primarily aimed at serious autoimmune diseases and inflammatory conditions, specifically GvHD, SLE, and systemic sclerosis.
3. Where is BioSenic headquartered?
BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium.
4. What is the purpose of the ATO platform developed by BioSenic?
The ATO platform is designed to create active products with immunomodulatory properties, particularly aimed at treating conditions such as chronic graft-versus-host disease.
5. How is BioSenic addressing its allogeneic cell therapy platform?
BioSenic is focusing on its allogeneic cell therapy platform by utilizing differentiated bone marrow MSCs to isolate and develop biological components that could aid in organ repair.
